Comparison of prognostic scores in transplant-ineligible patients with peripheral T-cell lymphoma not otherwise specified and angioimmunoblastic T-cell lymphoma: a retrospective study from the national hospital organization in Japan

References

• Swerdlow SH, Campo E, Harris NL, et al. WHO classification of tumours of haematopoietic and lymphoid tissues. Lyon, France: IARC Press; 2017.
   Google Scholar
• Vose J, Armitage J, Weisenburger D, International T-Cell Lymphoma Project. International peripheral T-cell and natural killer/T-cell lymphoma study: pathology findings and clinical outcomes. J Clin Oncol. 2008;26(25):4124–4130.
   PubMed Web of Science ®Google Scholar
• Schmitz N, de Leval L. How I manage peripheral T-cell lymphoma, not otherwise specified and angioimmunoblastic T-cell lymphoma: current practice and a glimpse into the future. Br J Haematol. 2017;176(6):851–866.
   PubMed Web of Science ®Google Scholar
• Chihara D, Fanale MA, Miranda RN, et al. The survival outcome of patients with relapsed/refractory peripheral T-cell lymphoma-not otherwise specified and angioimmunoblastic T-cell lymphoma. Br J Haematol. 2017;176(5):750–758.
   PubMed Web of Science ®Google Scholar
• Cheson BD. Novel therapies for peripheral T-cell non-Hodgkin’s lymphomas. Curr Opin Hematol. 2009;16:299–305.
   PubMed Web of Science ®Google Scholar
• Maruyama D, Tobinai K, Ogura M, et al. Romidepsin in Japanese patients with relapsed or refractory peripheral T-cell lymphoma: a phase I/II and pharmacokinetics study. Int J Hematol. 2017;106(5):655–665.
   PubMed Web of Science ®Google Scholar
• Gisselbrecht C, Sibon D. New perspectives in the therapeutic approach of peripheral T-cell lymphoma. Curr Opin Oncol. 2018;30(5):285–291.
   PubMed Web of Science ®Google Scholar
• Kharfan-Dabaja MA, Kumar A, Ayala E, et al. Clinical practice recommendations on indication and timing of hematopoietic cell transplantation in mature T cell and NK/T cell lymphomas: an international collaborative effort on behalf of the Guidelines Committee of the American Society for Blood and Marrow Transplantation. Biol Blood Marrow Transplant. 2017;23(11):1826–1838.
   PubMed Web of Science ®Google Scholar
• Rohlfing S, Dietrich S, Witzens-Harig M, et al. The impact of stem cell transplantation on the natural course of peripheral T-cell lymphoma: a real-world experience. Ann Hematol. 2018;97(7):1241–1250.
   PubMed Web of Science ®Google Scholar
• Ansell SM, Habermann TM, Kurtin PJ, et al. Predictive capacity of the International Prognostic Factor Index in patients with peripheral T-cell lymphoma. J Cin Oncol. 1997;15(6):2296–2301.
   PubMed Web of Science ®Google Scholar
• Gallamini A, Stelitano C, Calvi R, et al. Peripheral T-cell lymphoma unspecified (PTCL-U): a new prognostic model from a retrospective multicentric clinical study. Blood. 2004;103(7):2474–2479.
   PubMed Web of Science ®Google Scholar
• Went P, Agostinelli C, Gallamini A, et al. Marker expression in peripheral T-cell lymphoma: a proposed clinical-pathologic prognostic score. J Cin Oncol. 2006;24(16):2472–2479.
   PubMed Web of Science ®Google Scholar
• Weisenburger DD, Savage KJ, Harris NL, for the International Peripheral T-cell Lymphoma Project, et al. Peripheral T-cell lymphoma, not otherwise specified: a report of 340 cases from the International Peripheral T-cell Lymphoma Project. Blood. 2011;117(12):3402–3408.
   PubMed Web of Science ®Google Scholar
• Gutiérrez-García G, García-Herrera A, Cardesa T, et al. Comparison of four prognostic scores in peripheral T-cell lymphoma. Ann Oncol. 2011;22(2):397–404.
   PubMed Web of Science ®Google Scholar
• Cheson BD, Pfistner B, Juweid ME, International Harmonization Project on Lymphoma, et al. International Harmonization Project on Lymphoma Revised response criteria for malignant lymphoma. J Clin Oncol. 2007;25(5):579–586.
   PubMed Web of Science ®Google Scholar
• Harrell FE, Jr, Lee KL, Mark DB. Multivariable prognostic models: issues in developing models, evaluating assumptions and adequacy, and measuring and reducing errors. Statist Med. 1996;15(4):361–387.
   PubMed Web of Science ®Google Scholar
• Kanda Y. Investigation of the freely available easy-to-use software 'EZR' for medical statistics. Bone Marrow Transplant. 2013;48(3):452–458.
   PubMed Web of Science ®Google Scholar
• Yamasaki S, Chihara D, Kim SW, et al. Risk factors and timing of autologous stem cell transplantation for patients with peripheral T-cell lymphoma. Int J Hematol. 2019;109(2):175–186.
   PubMed Web of Science ®Google Scholar
• Ellin F, Maurer MJ, Srour L, et al. Comparison of the NCCN-IPI, the IPI and PIT scores as prognostic tools in peripheral T-cell lymphomas. Br J Haematol. 2019;186(3):e24–e27.
   PubMed Web of Science ®Google Scholar
• Ellin F, Landström J, Jerkeman M, et al. Real-world data on prognostic factors and treatment in peripheral T-cell lymphomas: a study from the Swedish Lymphoma Registry. Blood. 2014;124(10):1570–1577.
   PubMed Web of Science ®Google Scholar
• Moskowitz AJ, Lunning MA, Horwitz SM. How I treat the peripheral T-cell lymphomas. Blood. 2014;123(17):2636–2644.
   PubMed Web of Science ®Google Scholar
• Simon A, Peoch M, Casassus P, et al. Upfront VIP-reinforced-ABVD (VIP-rABVD) is not superior to CHOP/21 in newly diagnosed peripheral T cell lymphoma. Results of the randomized phase III trial GOELAMS-LTP95. Br J Haematol. 2010;151(2):159–166.
   PubMed Web of Science ®Google Scholar
• National Comprehensive Cancer Network. NCCN Clinical Practice Guidelines in Oncology, T-Cell Lymphomas (Version 1.2020). [cited 2020 Nov 2]. Available from: https://www.nccn.org/professionals/physician_gls/pdf/t-cell.pdf.
   Google Scholar
• d'Amore F, Gaulard P, Trümper L, et al. Peripheral T-cell lymphomas: ESMO Clinical Practice Guidelines for diagnosis, treatment and follow-up. Ann Oncol. 2015;26(Suppl 5):v108–15.
   PubMed Web of Science ®Google Scholar
• Buske C, Hutchings M, Ladetto M, ESMO Lymphoma Consensus Conference Panel Members, et al. ESMO Consensus Conference on malignant lymphoma: general perspectives and recommendations for the clinical management of the elderly patient with malignant lymphoma. Ann Oncol. 2018;29(3):544–562.
   PubMed Web of Science ®Google Scholar
• Maeda Y, Nishimori H, Yoshida I, et al. Dose-adjusted EPOCH chemotherapy for untreated peripheral T-cell lymphomas: a multicenter phase II trial of West-JHOG PTCL0707. Haematologica. 2017;102(12):2097–2103.
   PubMed Web of Science ®Google Scholar
• Horwitz S, O'Connor OA, Pro B, ECHELON-2 Study Group, et al. Brentuximab vedotin with chemotherapy for CD30-positive peripheral T-cell lymphoma (ECHELON-2): a global, double-blind, randomised, phase 3 trial. Lancet. 2019;393(10168):229–240.
   PubMed Web of Science ®Google Scholar
• Wudhikarn K, Bunworasate U, Julamanee J, on behalf of Thai Lymphoma Study Group, et al. Event free survival at 24 months is a strong surrogate prognostic endpoint of peripheral T cell lymphoma. Hematol Oncol. 2019;37(5):578–585.
   PubMed Web of Science ®Google Scholar
• Maurer MJ, Ellin F, Srour L, et al. International assessment of event-free survival at 24 months and subsequent survival in peripheral T-cell lymphoma. J Clin Oncol. 2017;35(36):4019–4026.
   PubMed Web of Science ®Google Scholar
• Shi Q, Flowers CR, Hiddemann W, et al. Thirty-month complete response as a surrogate end point in first-line follicular lymphoma therapy: an individual patient-level analysis of multiple randomized Trials. J Clin Oncol. 2017;35(5):552–560.
   PubMed Web of Science ®Google Scholar
• Magnano L, Alonso-Alvarez S, Alcoceba M, Grupo Español de Linfomas y Trasplante Autólogo de Médula Ósea (GELTAMO), et al. Life expectancy of follicular lymphoma patients in complete response at 30 months is similar to that of the Spanish general population. Br J Haematol. 2019;185(3):480–491.
   PubMed Web of Science ®Google Scholar
• Yamasaki S, Yoshida S, Kato K, et al. Effects of stem cell transplantation in p atients with peripheral T-cell lymphoma not otherwise specified and angioimmunoblastic T-cell lymphoma. Int J Hematol. 2020;112:74–83.
   PubMed Web of Science ®Google Scholar